https://www.selleckchem.com/pr....oducts/Decitabine.ht
Psoriasis is a chronic, inflammatory disease that may differ in prevalence and clinical presentation among patients from various racial and ethnic groups. Two phase 3 studies demonstrated efficacy and safety of halobetasol propionate (HP) 0.01% lotion in the treatment of moderate-to-severe plaque psoriasis (NCT02514577, NCT02515097). These post hoc analyses evaluated HP 0.01% lotion in Hispanic participants. Participants were randomized (21) to receive once-daily HP or vehicle lotion for 8 weeks, with a 4-week posttreatment follow-up
Curtir
Comentario
Compartilhar
